These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 16715358)

  • 21. Effects of demographic variables on vorozole pharmacokinetics in healthy volunteers and in breast cancer patients.
    Piotrovsky VK; Huang ML; Van Peer A; Langenaecken C
    Cancer Chemother Pharmacol; 1998; 42(3):221-8. PubMed ID: 9685057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of dosing strategy for pembrolizumab for oncology indications.
    Freshwater T; Kondic A; Ahamadi M; Li CH; de Greef R; de Alwis D; Stone JA
    J Immunother Cancer; 2017; 5():43. PubMed ID: 28515943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer.
    Bruno R; Washington CB; Lu JF; Lieberman G; Banken L; Klein P
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):361-9. PubMed ID: 15868146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial.
    Ng CM; Bruno R; Combs D; Davies B
    J Clin Pharmacol; 2005 Jul; 45(7):792-801. PubMed ID: 15951469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vancomycin dosing in children and young adults: back to the drawing board.
    Camaione L; Elliott K; Mitchell-Van Steele A; Lomaestro B; Pai MP
    Pharmacotherapy; 2013 Dec; 33(12):1278-87. PubMed ID: 24019205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel.
    Cortés J; Swain SM; Kudaba I; Hauschild M; Patel T; Grincuka E; Masuda N; McNally V; Ross G; Brewster M; Marier JF; Trinh MM; Garg A; Nijem I; Visich J; Lum BL; Baselga J
    Anticancer Drugs; 2013 Nov; 24(10):1084-92. PubMed ID: 23969513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors.
    Tan AR; Moore DF; Hidalgo M; Doroshow JH; Poplin EA; Goodin S; Mauro D; Rubin EH
    Clin Cancer Res; 2006 Nov; 12(21):6517-22. PubMed ID: 17065274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing.
    Mross K; Holländer N; Frost A; Unger C; Ziroli V; Massing U
    Onkologie; 2006 Oct; 29(10):444-50. PubMed ID: 17028453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetic evaluation of a fully human IgG monoclonal antibody in patients with inflammatory diseases.
    Tabrizi M; Wang B; Lu H; Huang S; Bell G; Schwab G; Roskos L
    Inflamm Allergy Drug Targets; 2010 Sep; 9(4):229-37. PubMed ID: 20860546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.
    Gordon MS; Matei D; Aghajanian C; Matulonis UA; Brewer M; Fleming GF; Hainsworth JD; Garcia AA; Pegram MD; Schilder RJ; Cohn DE; Roman L; Derynck MK; Ng K; Lyons B; Allison DE; Eberhard DA; Pham TQ; Dere RC; Karlan BY
    J Clin Oncol; 2006 Sep; 24(26):4324-32. PubMed ID: 16896006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.
    de Jongh FE; Verweij J; Loos WJ; de Wit R; de Jonge MJ; Planting AS; Nooter K; Stoter G; Sparreboom A
    J Clin Oncol; 2001 Sep; 19(17):3733-9. PubMed ID: 11533095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of body mass index on pharmacokinetics of paclitaxel in patients with early breast cancer.
    Gota V; Nookala M; Bonda A; Karanam A; Shriyan B; Kembhavi Y; Gurjar M; Patil A; Singh A; Goyal N; Gupta S
    Cancer Med; 2021 May; 10(9):3068-3076. PubMed ID: 33826243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations.
    Lebwohl M; Yeilding N; Szapary P; Wang Y; Li S; Zhu Y; Reich K; Langley RG; Papp KA
    J Am Acad Dermatol; 2010 Oct; 63(4):571-9. PubMed ID: 20599293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor.
    Kakkar T; Sung C; Gibiansky L; Vu T; Narayanan A; Lin SL; Vincent M; Banfield C; Colbert A; Hoofring S; Starcevic M; Ma P
    Pharm Res; 2011 Oct; 28(10):2530-42. PubMed ID: 21604075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.
    Zhou H; Jang H; Fleischmann RM; Bouman-Thio E; Xu Z; Marini JC; Pendley C; Jiao Q; Shankar G; Marciniak SJ; Cohen SB; Rahman MU; Baker D; Mascelli MA; Davis HM; Everitt DE
    J Clin Pharmacol; 2007 Mar; 47(3):383-96. PubMed ID: 17322150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.
    Trame MN; Bergstrand M; Karlsson MO; Boos J; Hempel G
    Clin Cancer Res; 2011 Nov; 17(21):6867-77. PubMed ID: 21918171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.
    Han K; Jin JY; Marchand M; Eppler S; Choong N; Hack SP; Tikoo N; Bruno R; Dresser M; Musib L; Budha NR
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):917-24. PubMed ID: 26365290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support.
    Shen M; Schilder RJ; Obasaju C; Gallo JM
    Cancer Chemother Pharmacol; 2002 Sep; 50(3):243-50. PubMed ID: 12203107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dosing algorithm revisit for busulfan following IV infusion.
    Wang Y; Kato K; Le Gallo C; Armstrong E; Rock E; Wang X
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):505-12. PubMed ID: 25561350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.